We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Tag: Helicobacter pylori
MedXY News
EnglishTag

Helicobacter pylori

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Reevaluating the Link Between Helicobacter pylori Infection and Insulin Resistance: Insights from Frequentist and Bayesian Analyses in a European Cohort
Diabetes & Endocrinologymetabolic syndromeHelicobacter pylori

Reevaluating the Link Between Helicobacter pylori Infection and Insulin Resistance: Insights from Frequentist and Bayesian Analyses in a European Cohort

By MedXY|Aug 25, 2026

A comprehensive European cohort study reveals that Helicobacter pylori infection’s association with insulin resistance is confounded by socioeconomic and lifestyle factors, arguing against its independent causal role and the need for

Helicobacter pylori Infection and Colorectal Cancer: Genetic Risk Links and Treatment Outcomes from Two Long-Term Randomized Trials
Gastroenterologycolorectal cancergenetic predisposition

Helicobacter pylori Infection and Colorectal Cancer: Genetic Risk Links and Treatment Outcomes from Two Long-Term Randomized Trials

By MedXY|Jul 1, 2026

Two large randomized trials reveal that Helicobacter pylori infection elevates colorectal cancer risk, particularly in individuals with specific bacterial virulence factors or high genetic susceptibility, and that eradication treatment may

The Unfinished Agenda in Helicobacter pylori Treatment: Resistance, Microbiome Effects, and Future Directions
Clinical UpdatesAntimicrobial ResistanceHelicobacter pylori

The Unfinished Agenda in Helicobacter pylori Treatment: Resistance, Microbiome Effects, and Future Directions

By MedXY|Apr 5, 2026

This review synthesizes the evolving landscape of H. pylori management, highlighting the rise of P-CAB-based therapies, the impact of antibiotic resistance on global eradication strategies, and the expanding recognition of extragastric dise

Precision Genomics Outperforms Empirical Approaches in Managing Drug-Resistant Helicobacter pylori
Gastroenterologyantibiotic resistanceHelicobacter pylori

Precision Genomics Outperforms Empirical Approaches in Managing Drug-Resistant Helicobacter pylori

By MedXY|Dec 29, 2025

A global genomic study of Helicobacter pylori reveals that mutations in 23S rRNA and gyrA predict antibiotic resistance with 100% sensitivity, signaling the end of empirical therapy in favor of genotype-based personalized treatment.

Optimized Bismuth Quadruple Therapy Surpasses Standard Triple Therapy for First-Line H. pylori Eradication
GastroenterologyAntimicrobial Resistancegastroenterology

Optimized Bismuth Quadruple Therapy Surpasses Standard Triple Therapy for First-Line H. pylori Eradication

By MedXY|Dec 19, 2025

A double-blind RCT in Chile demonstrates that a 14-day optimized bismuth quadruple therapy achieves a 95% eradication rate for Helicobacter pylori, significantly outperforming standard triple therapy without increasing the burden of adverse

Rifasutenizol-Based Triple Therapy Versus Bismuth Plus Clarithromycin Triple Therapy for First-Line Helicobacter pylori Eradication: Analysis of the EVEREST-HP Phase 3 Trial in China
Clinical UpdatesAntimicrobial ResistanceHelicobacter pylori

Rifasutenizol-Based Triple Therapy Versus Bismuth Plus Clarithromycin Triple Therapy for First-Line Helicobacter pylori Eradication: Analysis of the EVEREST-HP Phase 3 Trial in China

By MedXY|Nov 24, 2025

EVEREST-HP demonstrates that rifasutenizol-based triple therapy offers non-inferior H. pylori eradication with improved tolerability compared to bismuth plus clarithromycin triple therapy in treatment-naive Chinese patients.

Taipei Global Consensus II (2025): A Practical Guide to Helicobacter pylori Screening and Eradication for Gastric Cancer Prevention
GastroenterologyguidelineHelicobacter pylori

Taipei Global Consensus II (2025): A Practical Guide to Helicobacter pylori Screening and Eradication for Gastric Cancer Prevention

By MedXY|Nov 7, 2025

An evidence-based synthesis of the 2025 Taipei Global Consensus II: 28 statements guiding H. pylori screening, eradication, surveillance and stewardship to reduce gastric cancer at individual and population levels.

Enhancing Helicobacter pylori Eradication: The Role of Probiotics Pretreatment
Gastroenterologyeradication therapygut microbiome

Enhancing Helicobacter pylori Eradication: The Role of Probiotics Pretreatment

By MedXY|Oct 6, 2025

Probiotic pretreatment improves Helicobacter pylori eradication rates and reduces side effects, offering a promising adjunctive strategy to overcome treatment challenges and antibiotic resistance.

Routine Helicobacter pylori Screening Post-Myocardial Infarction: Insights from the HELP-MI SWEDEHEART Trial
CardiologyHelicobacter pylorimyocardial infarction

Routine Helicobacter pylori Screening Post-Myocardial Infarction: Insights from the HELP-MI SWEDEHEART Trial

By MedXY|Oct 6, 2025

Routine H. pylori screening after acute myocardial infarction does not significantly reduce upper gastrointestinal bleeding incidence; targeted screening in anemia or kidney failure subgroups may offer benefit.

Routine Helicobacter pylori Screening Post-Myocardial Infarction: Insights from the HELP-MI SWEDEHEART Trial
CardiologyHelicobacter pylorimyocardial infarction

Routine Helicobacter pylori Screening Post-Myocardial Infarction: Insights from the HELP-MI SWEDEHEART Trial

By MedXY|Oct 6, 2025

In a large Swedish cluster-randomized trial, routine Helicobacter pylori screening after acute myocardial infarction did not significantly reduce upper gastrointestinal bleeding, though high-risk subgroups may benefit.

Eradication of Helicobacter pylori Significantly Reduces Gastric Cancer Incidence and Mortality, with Clearer Benefits in High-Risk Populations
Clinical Updatescancer preventioneradication therapy

Eradication of Helicobacter pylori Significantly Reduces Gastric Cancer Incidence and Mortality, with Clearer Benefits in High-Risk Populations

By MedXY|Oct 1, 2025

A comprehensive meta-analysis confirms that Helicobacter pylori eradication reduces gastric cancer risk and related deaths, especially benefiting high-risk groups, supporting widespread screening and treatment.

Is Your Practice Missing the Next Gastric Cancer Surge?
Medical Newscancer preventionGastric Cancer

Is Your Practice Missing the Next Gastric Cancer Surge?

By MedXY|Oct 1, 2025

A new study predicts 11.8 million gastric cancer cases linked to Helicobacter pylori infection among children born 2008-2017, urging stronger global prevention and vaccine development.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story